HeyJaredBryant Furlow
- Indexed articles, last 90 days
- 4
- Latest publication
- Sep 4, 2026
- Outlet visibility, for Oncology Nurse Advisor
- Top 5M sites
- Earliest in this view
- Jul 27, 2026
Latest articles
Polymetastatic Disease Management: New Roles for SABR and LDRT - Oncology Nurse Advisor (opens the original)
Read excerpt
Stereotactic ablative radiotherapy (SABR) plays a growing role in the management of limited stage 4 (oligometastatic) disease, durably improving local control and improving survival time for some patients with lung and prostate cancer.1-4 Oncology nurses play key roles in safe, patient-centered SABR treatment, from patient education, treatment coordination, to monitoring and management of acute and late treatment-related toxicities. Now, researchers are investigating something even more ambitiou
mRNA Cancer Vaccines Show Promise But Are Dogged by Misinformation (opens the original)
Read excerpt
mRNA-based cancer vaccine research is at a pivotal stage, with early findings suggesting these vaccines can generate long-lived T-cell responses and might help overcome resistance to immune checkpoint inhibitors — and, one day, could even open the door to universal cancer vaccines.1-8 “The advantage of using mRNA is you get high local concentrations in lymphoid organs where the immune responses are generated and low systemic levels where adverse events occur,” said Drew Weissman, MD, PhD, Robert
mRNA Cancer Vaccines Show Promise But Are Dogged by Misinformation - Oncology Nurse Advisor (opens the original)
Read excerpt
mRNA-based cancer vaccine research is at a pivotal stage, with early findings suggesting these vaccines can generate long-lived T-cell responses and might help overcome resistance to immune checkpoint inhibitors — and, one day, could even open the door to universal cancer vaccines.1-8 “The advantage of using mRNA is you get high local concentrations in lymphoid organs where the immune responses are generated and low systemic levels where adverse events occur,” said Drew Weissman, MD, PhD, Robert
mRNA Cancer Vaccines Show Promise but Are Dogged by Misinformation (opens the original)
Read excerpt
mRNA-based cancer vaccine research is at a pivotal stage, with early findings suggesting these vaccines can generate long-lived T-cell responses and might help overcome resistance to immune checkpoint inhibitors — and, one day, could even open the door to universal cancer vaccines.1-8 “The advantage of using mRNA is you get high local concentrations in lymphoid organs where the immune responses are generated and low systemic levels where adverse events occur,” said Drew Weissman, MD, PhD, Robert
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5M sites
For Oncology Nurse Advisor, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.